Tango Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
STOCKHOLM, May 23, 2024 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that Medivir's licensee, Tango Therapeutics (NASDAQ: TNGX; Tango), has announced that the phase 1/2 clinical trial of TNG348, a novel USP1 inhibitor, is being terminated due to toxicity observed in the initial study cohorts.
Tango Therapeutics Announces Discontinuation of TNG348 Program
Bicycle Therapeutics to raise $555M in one of the biggest PIPEs of the year: The company’s stock $BCYC was up 20% on Thursday morning after it announced the stock sale to healthcare investors, which included Deep Track Capital, EcoR1 Capital, Fairmount Capital, Forbion, Perceptive Advisors and RA Capital Management. Bicycle is set to present two posters at the upcoming ASCO meeting, which is the biggest cancer conference of the year. Abstracts are set to drop on Thursday evening. Bicycle declined to comment on whether the investors saw its ASCO data. — Lei Lei Wu
Tango Therapeutics said Thursday it has stopped development of an early-phase synthetic lethal cancer candidate after seeing liver toxicity in recipients of the molecule.
Tango Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Tango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Highlights
Tango Therapeutics to Participate in Upcoming Investor Conferences
Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline